Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative

Bioorganic & Medicinal Chemistry
Massimo GhizzoniFrank J Dekker

Abstract

Several lines of evidence indicate that histone acetyltransferases (HATs) are novel drug targets for treatment of diseases like, for example, cancer and inflammation. The natural product anacardic acid is a starting point for development of small molecule inhibitors of the histone acetyltransferase (HAT) p300/CBP associated factor (PCAF). In order to optimize the inhibitory potency, a binding model for PCAF inhibition by anacardic acid was proposed and new anacardic acid derivatives were designed. Ten new derivatives were synthesized using a novel synthetic route. One compound showed a twofold improved inhibitory potency for the PCAF HAT activity and a twofold improved inhibition of histone acetylation in HEP G2 cells.

Citations

Apr 26, 2011·Genes & Nutrition·Simone ReuterBharat B Aggarwal
Sep 4, 2012·Archives of Pharmacal Research·Woong Jae Park, Eunsook Ma
Sep 21, 2013·The Journal of Clinical Investigation·Kim RavnskjaerMarc Montminy
Apr 22, 2015·International Journal of Molecular Sciences·Fatma B Hamad, Egid B Mubofu
Oct 8, 2014·Journal of Cellular Biochemistry·Bryce K AllenNagi G Ayad
Jan 26, 2016·Pharmacology & Therapeutics·Stephanie KaypeeTapas K Kundu
May 26, 2012·Metabolism: Clinical and Experimental·Nima AlamdariPer-Olof Hasselgren
Nov 22, 2011·European Journal of Medicinal Chemistry·Massimo GhizzoniY George Zheng
Dec 25, 2015·Journal of Medicinal Chemistry·Roman P SimonManfred Jung
Apr 12, 2011·Drug Discovery Today·Massimo GhizzoniFrank J Dekker
Jan 7, 2017·Cell Death and Differentiation·Daniella BrasacchioJoseph A Trapani
Nov 7, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Woong Jae Park, Eunsook Ma
Feb 15, 2019·European Journal of Nutrition·Melina MitsiogianniMihalis I Panayiotidis
Feb 11, 2015·Oncogene·A FarriaS Y R Dent
Jan 12, 2012·Archiv der Pharmazie·Silviya D FurdasManfred Jung
May 6, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kangxian ZhaoYu Qian
Mar 31, 2019·International Journal of Molecular Sciences·Sungjin ChungHo-Shik Kim
Sep 10, 2020·Frontiers in Pharmacology·Francesco FiorentinoDante Rotili
Aug 20, 2020·Seminars in Cancer Biology·Margarita E NeganovaGjumrakch Aliev
Jun 3, 2021·Cancers·Ruicen HeKarl Riabowol
Apr 19, 2019·ACS Medicinal Chemistry Letters·Luiz Antonio Soares RomeiroMaria Laura Bolognesi
Jun 11, 2020·ACS Infectious Diseases·Marco SaedtlerLorenz Meinel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.